Serological cytokine signature in paediatric patients with inflammatory bowel disease impacts diagnosis

Tatsuki, Maiko; Hatori, Reiko; Nakazawa, Tomoko; Ishige, Takashi; Hara, Tomoko; Kagimoto, Seiichi; Tomomasa, Takeshi; Arakawa, Hirokazu; Takizawa, Takumi

doi:10.1038/s41598-020-71503-y

Cited by 15 publications

(19 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also growth-regulated oncogene and TNF-α were higher in UC than in controls. This study observed clear differences in cytokine profiles between CD and UC, with IL-7 alone having the highest diagnostic accuracy [36].…”

Section: Biomarkers From Gut Microbiotamentioning

confidence: 63%

New Metabolic and Genetic Biomarkers for Diagnosis of Ulcerative Colitis

Tudoroniu¹,

Costache²,

Stancu³

et al. 2021

Preprint

View full text Add to dashboard Cite

Ulcerative colitis (UC) is one of the two disorders known as inflammatory bowel diseases (IBD) along with Crohn’s disease (CD), with complex pathogenesis, requiring costly invasive investigations. Objective: to examine the most recent biomarkers proposed for UC diagnosis; to establish the strategy used to make the differential diagnosis between UC and CD relying on these biomarkers, also adding the benefit of finding new non-invasive tools in managing this condition. The search was performed in a single database (Web of Science) using the specific keywords &bdquo;ulcerative colitis”, &bdquo;biomarkers” and &bdquo;diagnosis” for the last five years. Study eligibility criteria: clinical trials on adults and pediatric patients with ulcerative colitis compared with Crohn’s disease. Results: We selected 57 studies, randomized controlled trials (RCTs) and clinical case series (CCS), summarizing the latest most specific biomarkers in diagnosis of UC. Limitations: we considered RCTs and CCS from one database, limited to the search topics. Our findings indicate a important number of potential biomarkers with diagnostic value, which bring the advantage of a non-invasive method to approach this challenging disorder.

show abstract

Section: Biomarkers From Gut Microbiotamentioning

confidence: 63%

New Metabolic and Genetic Biomarkers for Diagnosis of Ulcerative Colitis

Tudoroniu¹,

Costache²,

Stancu³

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…As described above, the cytokines present in saliva are the most extensively analyzed marker, although other analytes such as calprotectin, exosome-containing molecules, IgA, cortisol, amylase, and oxidative stress indicators have been proposed as indicators of the pathology status. Of the salivary components analyzed, IL-6 has the most interleukins studied, and the results are in accordance with an increase in its amount in the saliva both [ 21 , 36 , 37 , 38 , 47 ] in patients with CD and UC, whereas contradictory results have been observed for salivary TNF-α [ 21 , 36 ], circulating IL-6, and TNF-α, which are commonly used as indicators of disease activity in IBD and the state of endoscopic disease activity in IBD [ 88 , 89 ]. The key role of IL-6 in IBD is highlighted by the fact that the serum concentrations are directly correlated to the inflammatory disease activity.…”

Section: Discussionmentioning

confidence: 85%

Salivary Stress/Immunological Markers in Crohn’s Disease and Ulcerative Colitis

Finamore

Peluso

Cauli

2020

IJMS

View full text Add to dashboard Cite

There is continuous and growing interest in research into new alternatives to standard biomarkers to detect and follow-up disease, reducing physical and psychological stress in patients needing regular and invasive medical examinations for the evaluation of pathologies, including inflammatory bowel diseases (IBD). Saliva is one of the most promising body fluids in the research of new biomarkers, thanks to the large number of molecules it contains. Many molecules present in saliva are often directly correlated to their concentration in the blood but may be affected by the condition of the oral cavity. This means that a careful selection of a specific biomarker is required for each pathology, especially pathologies such as IBD, which may induce inflammation in the oral cavity. Here, we analyze the currently used and the proposed new salivary biomarkers (i.e., calprotectin, cytokines, IgA, cortisol, and oxidative stress markers) for the detection and follow-up of the main subtypes of IBD, known as ulcerative colitis and Crohn’s disease.

show abstract

“…Flow cytometric based assays can also be done with intracellular protein expression looking for deficiencies in FOXP3 leading to IPEX and XIAP especially in male patients (61,62). If available, cytokine and chemokine panels (IL-1, IL-2, IL-6, IL-10, IL-18, TNF-alpha, IFN-gamma) can be used to identify specific pathway defects, target treatment, and detect complications such as HLH development in XIAP (63,64). Endoscopy with histologic evaluation via hematoxylin and eosin (H+E) stain aids in the diagnosis of VEO-IBD though lacks diagnostic specificity.…”

Section: Discussionmentioning

confidence: 99%

The Growing Need to Understand Very Early Onset Inflammatory Bowel Disease

2021

View full text Add to dashboard Cite

Very Early Onset Inflammatory Bowel Disease (VEO-IBD) represents a cohort of inflammatory bowel disease (IBD) patients diagnosed before 6 years of age. Unlike IBD diagnosed at older ages, VEO-IBD can be associated with underlying primary immunodeficiencies. VEO-IBD has been linked to monogenic variations in over 70 genes involved in multiple pathways of immunity. As sequencing technologies and platforms evolve and become readily available, an increasing number of genes linked to VEO-IBD have emerged. Although monogenic defects are rare in VEO-IBD, diagnosis of these variants can often dictate specific treatment. In this mini-review, we set out to describe monogenic variants previously characterized in multiple patients in the literature that contribute to VEO-IBD, diagnostic tools, unique treatment modalities for specific genetic diagnoses, and future directions in the field of VEO-IBD. Although this mini-review is by no means comprehensive of all the novel monogenic variants linked to VEO-IBD, we hope to provide relevant information that is readily accessible to clinicians and educators.

show abstract

Serological cytokine signature in paediatric patients with inflammatory bowel disease impacts diagnosis

Cited by 15 publications

References 41 publications

New Metabolic and Genetic Biomarkers for Diagnosis of Ulcerative Colitis

New Metabolic and Genetic Biomarkers for Diagnosis of Ulcerative Colitis

Salivary Stress/Immunological Markers in Crohn’s Disease and Ulcerative Colitis

The Growing Need to Understand Very Early Onset Inflammatory Bowel Disease

Contact Info

Product

Resources

About